
Journey Medical Launches Emrosi, a Dual-Release Minocycline for Rosacea
Journey Medical Corporation announced today it has officially launched Emrosi (40 mg minocycline hydrochloride modified-release capsules) for the treatment of rosacea.1 The launch follows the US FDA approval of Emrosi, formerly DFD-29, in November 2024.2 …